Waypoint Bio raises $20.0M (China, May 2026)
$20.0M
$20MGenerated social card
Headline
Exclusive: Waypoint Bio raises $20M to run three CAR-T trials in China - Endpoints News
About
Waypoint Bio is a biotechnology company focused on developing innovative CAR-T therapies. The company aims to address unmet medical needs in cancer treatment through its clinical trials in China. This funding will support the execution of three CAR-T trials, highlighting the company's commitment to advancing cancer therapies.
Article summary
Exclusive: Waypoint Bio raises $20M to run three CAR-T trials in China Endpoints News
Investors
Related rounds
| Jul 27, 2026 | Photon Matrix Lab | $2.7M | — | China |
| Jul 25, 2026 | Ant International | $1.20B | — | China |
| Jul 22, 2026 | Zhipu AI | $40.0M | null | China |
| Jul 20, 2026 | LegendSpace | $29.5M | Angel | China |